c-Mpl-del, a c-Mpl alternative splicing isoform, promotes AMKL progression and chemoresistance

Abstract

Acute megakaryocytic leukemia (AMKL) is a clinically heterogeneous subtype of acute myeloid leukemia characterized by unrestricted megakaryoblast proliferation and poor prognosis. Thrombopoietin receptor c-Mpl is a primary regulator of megakaryopoeisis and a potent mitogenic receptor. Aberrant c-Mpl signaling has been implicated in a myriad of myeloid proliferative disorders, some of which can lead to AMKL, however, the role of c-Mpl in AMKL progression remains largely unexplored. Here, we identified increased expression of a c-Mpl alternative splicing isoform, c-Mpl-del, in AMKL patients. We found that c-Mpl-del expression was associated with enhanced AMKL cell proliferation and chemoresistance, and decreased survival in xenografted mice, while c-Mpl-del knockdown attenuated proliferation and restored apoptosis. Interestingly, we observed that c-Mpl-del exhibits preferential utilization of phosphorylated c-Mpl-del C-terminus Y607 and biased activation of PI3K/AKT pathway, which culminated in upregulation of GATA1 and downregulation of DDIT3-related apoptotic responses conducive to AMKL chemoresistance and proliferation. Thus, this study elucidates the critical roles of c-Mpl alternative splicing in AMKL progression and drug resistance, which may have important diagnostic and therapeutic implications for leukemia accelerated by c-Mpl-del overexpression.

RNA splicing regulator EIF3D regulates the tumor microenvironment through immunogene-related alternative splicing in head and neck squamous cell carcinoma

“…Genes exhibiting higher levels of AS tend to engage in more protein-protein interactions, thereby contributing to increased protein diversity. Additionally, splicing dysregulation can lead to isoform switching in oncogenes, enabling cancer cells to develop resistance to anticancer therapies [ 54 ]. In our study, we observed that the knockdown of EIF3D lead to alterations in various types of ASEs in FaDu cells.…”

METTL14 reverses liver fibrosis by inhibiting NOVA2 through an m6A-YTHDF2–dependent mechanism

“…Previous studies have found that the deletion or gene knockout of NOVA2 can prevent the normal formation of the vascular lumen. 24 – 38 The progression of LF is often accompanied by vascular proliferation, which promotes the activation and proliferation of HSC by furthering the transport of oxygen and nutrients, thus promoting the progress of LF. 29 – 32 The point is whether NOVA2 plays a key role in LF.…”

Advancements in Myeloid Leukemia Treatment: A Comprehensive Update

“…AEL is a rare subtype of AML characterized by prominent erythroid proliferation [22]. AMKL is characterized by the unrestricted proliferation of immature megakaryocytes (megakaryoblasts) and extensive myelofibrosis [23]. In addition to these subtypes, AML can be further classified based on specific genetic abnormalities.…”